1. Home
  2. RZLT vs VYGR Comparison

RZLT vs VYGR Comparison

Compare RZLT & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$2.99

Market Cap

326.4M

Sector

Health Care

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.96

Market Cap

194.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RZLT
VYGR
Founded
2010
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
326.4M
194.0M
IPO Year
2011
2015

Fundamental Metrics

Financial Performance
Metric
RZLT
VYGR
Price
$2.99
$3.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$9.67
$21.00
AVG Volume (30 Days)
2.9M
879.5K
Earning Date
05-12-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
26.32
N/A
EPS
N/A
N/A
Revenue
N/A
$10,135,000.00
Revenue This Year
N/A
$33.19
Revenue Next Year
N/A
$14.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$2.65
52 Week High
$11.46
$5.55

Technical Indicators

Market Signals
Indicator
RZLT
VYGR
Relative Strength Index (RSI) 51.61 48.26
Support Level $2.87 $3.61
Resistance Level $3.65 $4.43
Average True Range (ATR) 0.28 0.31
MACD 0.06 -0.04
Stochastic Oscillator 54.74 20.16

Price Performance

Historical Comparison
RZLT
VYGR

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: